Headlines about Checkpoint Therapeutics (NASDAQ:CKPT) have trended somewhat negative recently, Accern reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a media sentiment score of -0.09 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.6853785900783 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of research analysts recently issued reports on the company. Zacks Investment Research lowered Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright assumed coverage on Checkpoint Therapeutics in a research report on Friday, December 8th. They set a “buy” rating and a $11.00 price objective for the company.
NASDAQ:CKPT traded down $0.05 during midday trading on Friday, reaching $4.30. 23,661 shares of the company traded hands, compared to its average volume of 81,566. Checkpoint Therapeutics has a twelve month low of $3.20 and a twelve month high of $13.00. The firm has a market capitalization of $134.46 and a P/E ratio of -4.30.
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX.
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.